GleamWall
中文EN

COSM Cosmos Health Inc.

Wholesale-Drugs, Proprietaries & Druggists' Sundries · Nasdaq · SEC CIK 1474167 · Fiscal year ends 12/31

Financial factors as of 2026-06-30 (2026Q2), TTM = sum of the last four quarters

Growth

TTM revenue YoY33.8%
TTM net income YoY-13.1%
TTM EPS YoY35.6%
Revenue 3-yr CAGR14.8%
Net income 3-yr CAGR—

Margins

Gross margin10.3%
Operating margin-24.9%
Net margin-33.1%
FCF margin-13.5%
EBITDA margin-23.0%

Returns

ROE-104.0%
ROA-39.6%
ROIC (approx.)-54.8%
Asset turnover1.20x

Leverage & solvency

Liabilities / assets66.4%
Debt / equity0.15x
Current ratio1.05x
Interest coverage-7.80x

Cash quality & payout

Operating cash flow / net income0.40x
Accruals ratio-23.6%
Payout ratio—
Capex / revenue0.1%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-312024Q32024-09-30
Income statement
Revenue$18.99M$17.93M$19.70M$17.11M$14.75M$13.71M$14.22M$12.41M
Cost of revenue$17.47M$16.55M$17.62M$14.51M$13.58M$11.66M$13.22M$11.20M
Gross profit$1.51M$1.38M$2.08M$2.60M$1.16M$2.05M$1.00M$1.21M
R&D expense$68,552$0$410,760$18,337$74,637$15,629$533,293$0
SG&A expense$2.07M$1.80M$10.61M$2.04M$1.49M$1.48M$7.14M$1.78M
Operating income-$2.93M-$2.18M-$11.41M-$1.82M-$2.65M-$833,145-$8.97M-$2.24M
Interest expense$602,364$423,229$654,801$669,150$388,814$187,107$319,767$181,429
Pretax income-$6.09M-$2.81M-$10.15M-$5.35M-$2.83M-$818,097-$9.54M-$2.18M
Income tax$0$0$0$0$0$0$0$0
Net income-$6.09M-$2.81M-$10.15M-$5.35M-$2.83M-$818,097-$9.54M-$8.38M
EBITDA-$2.58M-$1.84M-$11.09M-$1.44M-$2.29M-$517,309-$8.66M-$1.94M
EPS (basic)-0.10-0.06—-0.17-0.10-0.03—-0.45
EPS (diluted)-0.10-0.06—-0.17-0.10-0.03—-0.45
Weighted avg. shares (diluted)59.92M47.09M—30.63M28.75M26.04M—18.42M
Balance sheet
Cash & equivalents$1.80M$514,702$715,674$889,441$655,503$742,881$315,105$3.31M
Short-term investments$37,464$34,225$46,158$33,178$30,266$25,278$21,148$22,808
Receivables$18.86M$18.19M$19.63M$18.03M$15.46M$14.25M$13.48M$17.48M
Inventory$4.52M$5.65M$5.78M$5.68M$5.11M$4.74M$4.36M$4.89M
Current assets$36.67M$36.89M$38.39M$38.10M$30.56M$27.84M$25.46M$36.24M
PP&E, net$10.14M$10.28M$10.58M$10.66M$10.82M$10.02M$9.69M$10.58M
Goodwill$49,697$49,697$49,697$49,697$49,697$49,697$49,697$49,697
Intangibles$6.92M$7.18M$7.52M$7.91M$8.18M$7.75M$7.71M$7.70M
Total assets$61.46M$62.37M$65.48M$69.49M$61.84M$57.19M$54.31M$64.52M
Current liabilities$34.84M$34.08M$38.27M$38.53M$31.17M$26.59M$25.76M$25.21M
Long-term debt$3.19M$3.45M$3.78M$5.37M$5.19M$4.85M$4.11M$4.27M
Total debt$3.19M$3.45M$3.78M$5.37M$5.19M$4.85M$4.11M$4.27M
Total liabilities$40.79M$42.54M$47.05M$46.36M$35.60M$31.24M$29.78M$29.54M
Shareholders' equity$20.67M$19.83M$18.42M$23.13M$26.23M$25.95M$24.53M$34.98M
Net debt$1.39M$2.94M$3.06M$4.48M$4.54M$4.11M$3.79M$953,127
Shares outstanding80.67M41.07M41.07M31.87M29.72M27.20M23.60M23.26M
Cash flow statement
Operating cash flow-$1.72M-$1.07M-$4.60M-$2.46M-$1.21M-$186,316-$3.83M$739,774
Capital expenditure$63,637$11,399$7,895$12,716$22,534$12,530$72,482$228,767
Free cash flow-$1.78M-$1.08M-$4.60M-$2.47M-$1.23M-$198,846-$3.91M$511,007
Investing cash flow$114,605-$708,963-$1.07M-$1.01M$71,820-$7,069-$1.01M-$35,433
Financing cash flow$1.79M$347,627$4.70M$7.19M$1.60M$560,862$1.62M$2.68M
Depreciation & amortization$349,181$346,520$315,145$377,911$353,862$315,836$304,862$304,139
Stock-based compensation$558,858$535,786$582,008$0$0$556,611$586,512$0
Share buybacks——————$0—

Free plan shows the latest 8 periods; Pro shows all 68 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.